Modelling rare and common diseases using iPS-derived cells

  • Research type

    Research Study

  • Full title

    Modelling rare and common diseases using iPS-derived cells at the Wellcome Trust Sanger Institute

  • IRAS ID

    182903

  • Contact name

    Daniel Gaffney

  • Contact email

    dg13@sanger.ac.uk

  • Sponsor organisation

    Genome Research Ltd. (operating as the Wellcome Trust Sanger Institute)

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    The HIPSCI (Human Induced Pluripotent Stem Cells Initiative) project (http://www.hipsci.org/) was funded by the Wellcome Trust and Medical Research Council (MRC) to create a catalogue of high-quality induced pluripotent stem cells (iPS cells). The project provides a knowledge-base to underpin the use of such cells in studying the effects of our genes on health and disease, and is creating a new iPS cell bank, including using samples from Cambridge BioResource volunteers, to provide a world-class resource for researchers. The cell-lines we wish to use in this current study have been made at the Sanger Institute as part of the HIPSCI project. We propose to generate additional cell-lines, to carry out research and to distribute all these cell-lines (including the original HIPSCI cell-lines and the new cell-lines created from these) so they can be used by the academic community and by industry.

    The research we would like to conduct with HIPSCI iPSCs will fall into one of the following areas: (i) detailed study of the molecular and cellular processes that occur during normal human development, and how these processes are altered by disease-causing mutations; (ii) studies of a range of different cell types in large numbers of samples to understand how genetic differences influence important cellular traits; (iii) the study of individual, rare, disease-causing mutations across a large range of cell types and tissues to understand how diseases manifest across the entire human body (rare disease cohorts will be added as future amendments to this application); (iv) the use of genetic screening technology to understand gene functions both during embryonic development and in adult tissue.

    Each of these study types will require the collection of a wide range of molecular, including whole genome, and cellular data that will enable us to understand the function of genes and mutations in great detail.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    15/YH/0391

  • Date of REC Opinion

    11 Aug 2015

  • REC opinion

    Favourable Opinion